Compare Gilead Sciences, Inc. (GILD) vs SPDR Gold Trust (GLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs SPDR Gold Trust — how do they compare? Gilead Sciences, Inc. trades at $135.19 (market cap $168.35B), while SPDR Gold Trust trades at $404.4. The key difference: Gilead Sciences, Inc. pays a 2.42% dividend while SPDR Gold Trust pays none. Which is the better fit depends on your goals.
| GILD | GLD | |
|---|---|---|
Market Cap | $168.35B | — |
Sector | Health | — |
52-Week High | $155.80 | $495.90 |
52-Week Low | $110.56 | $305.27 |
Enterprise Value | $191.42B | — |
Dividend Yield | 2.42% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About SPDR Gold Trust
GLD is the largest physically backed gold ETF in the world. It offers investors a cost-efficient and secure way to track the price of gold bullion without the need for physical storage.
Read more on GLD →
